onkologie *heute* 05/2023

Früherkennung bei familiärer Brustkrebsdisposition: Wie viel und was ist gut für die Ratsuchende? (S. 9–18)

F. Dammann, S. Ditz

Literatur:

1. S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms. Version 4.3. 2020. AWMF-Registernummer: 032-045OL. (http://www.leitlinienprogramm-onkologie .de/leitlinien/mammakarzinom). Zugegriffen am 03.11.2022
2. Arbeitsgemeinschaft Gynäkologische Onkologie e. V. Früherkennung und Diagnostik. (https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma). Zugegriffen am 03.11.2022
3. Deutsches Konsortium Familiärer Brust- und Eierstockkrebs. Konsensusempfehlungen des Konsortiums (Stand 2022). (https://www.konsortium-familiaerer-brustkrebs.de/konsensusempfehlung/). Zugegriffen am 03.11.2022
4. Robert Koch-Institut, Zentrum für Registerdaten. Brust- krebs (Mammakarzinom). (https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs_node.html#:~:text=Brustkrebs%20(Mammakarzinom)&text=Mit%20zuletzt%20rund%2071.375%20Neuerkrankungen,Prozent%20aller%20Neuerkrankungen%20betri%EF%AC%80t%20 M%C3%A4nner.). Zugegriffen am 03.11.2022
5. Antoniou A et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117–30
6. Goldberg JI & Borgen PI. Breast cancer susceptibility testing: past, present and future. Expert Rev Anticancer Ther 2006; 6: 1205–14
7. Engel C et al. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance. Int J Cancer 2020; 146: 999–1009
8. Fachal L et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet 2020; 52: 56–73
9. Dorling L et al. Breast Cancer Association Consortium. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med 2021; 384: 428–39
10. Hu C et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med 2021; 384: 440–51
11. Yang X et al. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. J Natl Cancer Inst 2020; 112: 1242–50
12. Alm El-Din MA et al. Breast cancer after treatment of Hodgkin‘s lymphoma: risk factors that really matter. Int J Radiat Oncol Biol Phys 2009; 73: 69–74
13. Preston DL et al. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 2002; 158: 220–35
14. Travis LB et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97: 1428–1437.
15. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004; 23: 1111–30

16. Ikonopedia. IBIS (International Breast Cancer Intervention Study). Online Tyrer-Cuzick model breast cancer risk evaluation tool – IBIS risk assessment tool v8 .0b. (https://ibis.ikonopedia .com/). Zugegriffen am 03.11.2022
17. Bundesministerium für Gesundheit. Krebsfrüherkennungsuntersuchung in der gesetzlichen Krankenversicherung (§ 25 Abs. 2 SGB V) /Mammographie. Informationsblatt Nr. 315-02. (https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/M/Mammografie/Infoblatt_Krebsfrueherkennung_Mammographie .pdf). Zugegriffen 03.11.2022
18. Deutsches Konsortium Familiärer Brust- und Eierstockkrebs. Intensivierte Früherkennung. Früherkennung durch moderne Bildgebung. (https://www.konsortium-familiaerer-brustkrebs .de/betreuungskonzept/praevention/intensivierte-frueherkennung/). Zugegriffen am 03.11.2022
19. Jakub JW et al. Oncologic Safety of Prophylactic Nipple- Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surg 2018; 153: 123–9
20. Jeffers L et al. Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery. Cochrane Database Syst Rev 2019; 10: CD012894
21. Scheepens JCC et al. Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability. Breast 2021; 56: 61–9
22. Bick U et al. German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res Treat 2019; 175: 217–28
23. Gödde E. Erbliche Krebsdisposition: Familienplanung zwischen Angst und Verantwortung. EHK 2010; 59: 189–98
24. Langewitz W. Patientenzentrierte Kommunikation. In: Adler RH, Herzog W, Joraschky P, Köhle K, Langewitz W, Söllner W, Wesiak W, Hrsg. Uexküll, Psychosomatische Medizin. Theoretische Modelle und klinische Praxis. München: Urban & Fischer; 2011. S. 338–47

Der HER2-Rezeptor beim Mammakarzinom: eine Erfolgsgeschichte ist noch nicht zu Ende (S. 19–24)

N. Tauber, A. Niendorf, C. Lindner

Literatur:

1. Robert Koch-Institut. Krebs in Deutschland 2017/2018: Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., ; 2019. (https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2021/kid_2021_c50_brust.pdf?__blob=publicationFile)
2. Shih C et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981; 290(5803): 261–4
3. Perou CM et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747–52
4. Lindner C. Mammakarzinom im Wandel. Hamburger Ärzteblatt 2012; 11/12: 12–7

5. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61 Suppl 2: 1–13
6. Yarden Y & Sliwkowski MX. Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology 2001; 2(2): 127–37
7. King CR et al. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985; 229(4717): 974–6
8. Reese DM & Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997; 15(1): 1–8
9. Benz CC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992; 24(2): 85–95
10. Weigelt B & Reis-Filho JS. Activating mutations in HER2: neu opportunities and neu challenges. Cancer Discov 2013; 3(2): 145–7
11. Bose R et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013; 3(2): 224–37
12. Kreipe H & Sinn P. Prädiktive Mutationsdiagnostik bei Mammakarzinomen. Die Pathologie 2021; 42: 399–404
13. Ali SM et al. Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. J Clin Oncol 2014; 32(25): e88–91
14. Filho OM et al. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov 2021; 11(10): 2474–87
15. Slamon DJ et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine 2001; 344(11): 783–92
16. Marczyk VR et al. Overall Survival for HER2-Positive Breast Cancer Patients in the HER2-Targeted Era: Evidence From a Population-Based Study. Clin Breast Cancer 2022; 22(5): 418–23
17. Guimaraes Koch SS et al. International nonproprietary names for monoclonal antibodies: an evolving nomenclature system. MAbs 2022; 14(1): 2075078
18. Oh D-Y & Bang Y-J. HER2-targeted therapies — a role beyond breast cancer. Nature Reviews Clinical Oncology 2020; 17(1): 33–48
19. Rainer Böger JH. Biologika- wie sie Medizin verändern. Hamburger Ärzteblatt 2023; 03/2023: 12–7
20. Wolff AC et al. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. J Oncol Pract 2018; 14(7): 437–41
21. Garcia-Alvarez A et al. Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. Cancers 2021; 13(12): 2927
22. Leone JP & Leone BA. Breast cancer brain metastases: the last frontier. Exp Hematol Oncol 2015; 4: 33
23. Tarantino P et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. Journal of Clinical Oncology 2020; 38(17): 1951–62
24. Schettini F et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer 2021; 7(1)
25. Denkert C et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 2021; 22(8): 1151–61

26. Hurvitz SA et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023; 401(10371): 105–17
27. Modi S et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine 2022; 387(1): 9–20
28. Schneider D & Richling F. Trastuzumab-Deruxtecan. In: Schneider D, Richling F, editors. Datenbank Arzneimittel: Georg Thieme Verlag KG; 2023
29. Trail PA et al. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther 2018; 181: 126–42
30. Harbeck N & Schneeweiss A. DrugReport Trastuzumab-Deruxtecan. Drug Report Thieme 2022
31. Murthy RK et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine 2019; 382(7): 597–609
32. Astra Zeneca. First HER2-directed medicine to be approved for gastric cancer in the EU in more than a decade 2022. (https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-eu-for-gastric-cancer.html)
33. agency Em. Assessment Report Yervoy (Ipilimumab). 2011

Indol-3-Carbinol – ein Blockbuster in der Prävention und Behandlung von Brustkrebs? (S. 25–32)

M. Kraft, B. Pfeifer

Literatur:

1. Kocarnik JM et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol 2022; 8: 420–44
2. Sung H et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209–49
3. Waks AG, Winer EP. Breast Cancer Treatment. JAMA 2019; 321: 288
4. Hon JDC et al. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res 2016; 6(9): 1864–72
5. Rosen LS et al. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist 2010; 15(3): 216–35
6. Zou H et al. Roles of plant-derived bioactive compounds and related microRNAs in cancer therapy. Phytother Res 2021; 35: 1176–86
7. Iqbal J et al. Plant-derived anticancer agents: A green anticancer approach. Asian Pac J Trop Biomed 2017; 7: 1129–50
8. Leitzmann C. Characteristics and health benefits of phytochemicals. Complementary Med Res 2016; 23: 69–74
9. Avato P et al. Activity of saponins from Medicago species against HeLa and MCF-7 cell lines and their capacity to potentiate cisplatin effect. Anti-Cancer Agents Med Chem (Former Curr Med Chem-Anti-Cancer Agents) 2017; 17: 1508–18

10. Joshi P et al. Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer. Eur J Med Chem 2017; 138: 273–92
11. Talib WH. Anticancer and antimicrobial potential of plant-derived natural products. In Phytochemicals –Bioactivities and Impact on Health; Rasooli, I., Ed.; InTech: Rijeka, Croatia, 2011; pp. 141–58
12. Talib WH et al. Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation. Molecules 2020; 25: 5319
13. Rayan A et al. Nature is the best source of anticancer drugs: Indexing natural products for their anticancer bioactivity. PLoS ONE 2017; 12: e0187925.
14. Thakore P et al. A brief review of plants having anti-cancer property. Int J Pharm Res Dev 2012; 3: 129–36
15. Tariq A et al. A systematic review on ethnomedicines of anti-cancer plants. Phytother Res 2017; 31: 202–64
16. Hayes JD et al. The cancer chemopreventive actions of phytochemicals derived from glucosinolates. Eur J Nutr 2008; 47 Suppl 2: 73–88
17. Hecht SS. Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev 2000; 32: 395–411
18. Higdon JV et al. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 2007; 55: 224–36
19. Kirsh VA et al. Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst 2007; 99: 1200–9
20. Kolonel LN et al. Vegetables, fruits, legumes and prostate cancer: a multi-ethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000; 9: 795–804
21. Ambrosone CB et al. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr 2004; 134: 1134–8
22. Bell MC et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000; 78: 123–9
23. Cohen JH et al. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000; 92: 61–8
24. Giovannucci E et al. A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 1403–9
25. Murillo G, Mehta RG: Cruciferous vegetables and cancer prevention. Nutr Cancer 2001; 41: 17–28
26. Voorrips LE et al. Vegetable and fruit consumption and lung cancer risk in the Netherlands Cohort Study on diet and cancer. Cancer Causes Control 2000; 11: 101–15
27. Bradlow H et al. Effect of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 1991; 12: 1571–4
28. Chang X et al. 3,3'-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis 2005; 26: 771–8
29. Kojima T et al. Chemoprevention of spontaneous endometrial cancer in female Donryku rats by dietary indole-3-carbinol. Cancer Res 1994; 5: 1446–9
30. Rahman KM et al. Indole-3- carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutr Cancer 2003; 45: 101–12
31. Souli E et al. Indole-3-carbinol (I3C) exhibits inhibitory and preventive effects on prostate tumors in mice. Food Chem Toxicol 2008; 46: 815–28

32. Wattenberg LW, Loub WD. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res 1978; 38: 1410–3

33. Smith-Warner SA et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA 2001; 285: 769–76

34. Liu X, Lv K. Cruciferous vegetables intake is inversely associated with risk of breast cancer: a meta-analysis. Breast 2013; 22: 309–13

35. Rock CL et al. Longitudinal biological exposure to carotenoids is associated with breast cancer-free survival in the Women's Healthy Eating and Living Study. Cancer Epidemiol Biomarkers Prev 2009; 18(2): 486–94

36. Maina S et al. Human, animal, and plant health benefits of glucosinolates and strategies for enhanced bioactivity: a systematic review. Molecules 2020; 25:163682

37. Shakour ZT et al. Metabolic and biotransformation effects on dietary glucosinolates, their bioavailability, catabolism, and biological effects in different organisms. Biotechnol Adv 2022; 54:107784

38. Casajús V et al. Harvesting at different time-points of day affects glucosinolate metabolism during postharvest storage of broccoli. Food Res Int 2020; 136:109529

39. Palermo M et al. The effect of cooking on the phytochemical content of vegetables. J Sci Food Agric 2014; 94(6): 1057–70

40. Campbell LD, Slominski BA. Extent of thermal decomposition of indole glucosinolates during the processing of canola seed. J Am Oil Chem Soc 1990; 67(2): 73–5

41. Shapiro TA et al. Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Cancer Epidemiol Biomarkers Prev 1998; 7(12): 1091–100

42. Holst B, Williamson GA. A critical review of the bioavailability of glucosinolates and related compounds. Nat Prod Rep 2004; 21: 425–47

43. Stoewsand GS. Bioactive organosulfur phytochemicals in Brassica oleracea vegetables - A review. Food Chem Toxicol1995; 33: 537–43

44. Kassie F et al. Genotoxic effects of benzyl isothiocyanate: a natural chemopreventive agent. Mutagenesis 1999; 14: 595–604

45. Karin M, Greten FR. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749–59

46. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431–6

47. Haefner B. NF-kappa B: Arresting a major culprit in cancer. Drug Discov Today 2002; 7: 653–63

48. Song QQ et al. Characterization of LTr1 derived from cruciferous vegetables as a novel anti-glioma agent via inhibiting TrkA/PI3K/AKT pathway. Acta Pharmacol Sin 2022

49. Yuan L at al. Promoting Apoptosis, a Promising Way to Treat Breast Cancer with Natural Products: A Comprehensive Review. Front Pharmacol 2022; 12: 801662

50. Aggarwal BB, Ichikawa H. Molecular targets and antic- cancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005; 4: 1201–15

51. Chinni SR et al. Indole- 3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 2001; 20: 2927–36

52. Cover CM et al. Indole-3-carbinol inhibits the expression of cyclindependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 1998; 273: 3838–47

53. Firestone GL, Bjeldanes LF. Indole-3-carbinol and 3–3'diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human

breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J Nutr 2003; 133: 2448–55

54. Garcia HH et al. Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex. J Biol Chem 2005; 280: 8756–64

55. Hong C et al. Bcl-2 family-mediated apoptotic effects of 3,3'-diindolylmethane (DIM) in human breast cancer cells. Biochem Pharmacol 2002; 63: 1085–97

56. Hong C et al. 3,3'-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 2002; 23: 1297–305

57. Kim SJ et al. 3,3‵-Diindolylmethane suppresses growth of human esophageal squamous cancer cells by G1 cell cycle arrest. Oncol Rep 2012; 27: 1669–73

58. Ahmad A at al. Anticancer properties of indole compounds: Mechanism of apoptosis induction and role in chemotherapy. Curr Drug Targets 2010; 11: 652–66

59. McGuire KP et al. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. J Surg Res 2006; 132: 208–13

60. Wang H et al. Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1. Anticancer Res 2011; 31: 3171–80

61. Banerjee S et al. 3, 3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 2009; 69: 5592–5600

62. Christensen JG, LeBlanc GA. Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res 1996; 56: 574–81

63. Zhang J et al. 3,3'-Diindolylmethane Enhances Fluorouracil Sensitivity via Inhibition of Pyrimidine Metabolism in Colorectal Cancer. Metabolites 2022; 12(5): 410

64. Hajra S et al. Indole-3-Carbinol (I3C) enhances the sensitivity of murine breast adenocarcinoma cells to doxorubicin (DOX) through inhibition of NF-κβ, blocking angiogenesis and regulation of mitochondrial apoptotic pathway. Chem Biol Interact 2018; 290:19–36

65. Krajka-Kuźniak V, Baer-Dubowska W. Modulation of Nrf2 and NF-κB Signaling Pathways by Naturally Occurring Compounds in Relation to Cancer Prevention and Therapy. Are Combinations Better Than Single Compounds? Int J Mol Sciences 2021; 22(15): 8223

66. Ahmad A et al. 3,3‵-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells. PLoS ONE 2013; 8: e54657

67. Malejka-Giganti D et al. Suppression of mammary gland carcinogenesis by post-initiation treatment of rats with tamoxifen or indole-3-carbinol or their combination. Eur J Cancer Prev 2007; 16: 130–41

68. Taylor-Harding B et al. Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment. Br J Cancer 2012; 106: 333–43

69. Li Y, Li X, Guo B. Chemopreventive agent 3,3'-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res 2010; 70: 646–54

70. Wortelboer HM et al. Acid reaction products of indole-3-carbinol and their effects on cytochrome P450 and phase II enzymes in rat and monkey hepatocytes. Biochem Pharmacol 1992; 43: 1439–47

71. Saw CL et al. Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. Biopharm Drug Dispos 2011; 32: 289–300

72. Gross-Steinmeyer K et al. Modulation of aflatoxin B1-mediated genotoxicity in primary cultures of human hepatocytes by diindolylmethane, curcumin, and xanthohumols. Toxicol Sci 2009; 112: 303–10

73. Fan S et al. Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner. Cancer Res 2009; 69: 6083–91

74. Li Y et al. Antioxidant function of isoflavone and 3,3'-diindolylmethane: are they important for cancer prevention and therapy? Antioxid Redox Signal 2013; 19: 139–50

75. Cho HJ et al. 3,3'-Diindolylmethane suppresses the inflammatory response to lipopolysaccharide in murine macrophages. J Nutr 2008; 138: 17–23

76. Kim HW et.al. 3,3'-Diindolylmethane inhibits lipopolysaccharide-induced microglial hyperactivation and attenuates brain inflammation. Toxicol Sci 2014; 137: 158–67

77. Wang Z et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006; 66: 2778–84

78. Moiseeva EP et al. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther 2007; 6: 3071–9

79. Mao CG et al. Indole-3-carbinol inhibits nasopharyngeal carcinoma cell growth in vivo and in vitro through inhibition of the PI3K/Akt pathway. Exp Ther Med 2014; 8: 207–12

80. Rahman KM et al. Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells. Oncogene 2000; 19: 5764–71

81. Sarkar FH, Li Y, Wang Z, Kong D. Cellular signaling perturbation by natural products. Cell Signal 2009; 21: 1541–7

82. Stewart ZA et al. Cell cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 2003; 24: 139–45

83. Chinni SR et al. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 2001; 20: 927–30

84. Gong Y et al. 3,3'diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21 (Cip/ Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Res 2006; 66: 4880–7

85. Vivar O et al. 3,39-Diindolylmethane induces a G (1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. Biochem Pharmacol 2009; 78: 469–76

86. Rahman KM et al. Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutr Cancer 2003; 45: 101–12

87. Hientz K et al. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget 2017; 8: 8921–46

88. El-Kenawi A et al. The Immune Microenvironment and Cancer Metastasis. Cold Spring Harb Perspect Med 2020; 10(4): a037424

89. Asakage M et al. Sulforaphane induces inhibition of human umbilical vein endothelial cells proliferation by apoptosis. Angiogenesis 2006; 9: 83–91

90. Davis R et al. Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep 2009; 22: 1473–8

91. Chang X et al. 3,3'-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis 2005; 26: 771–8

92. Kong D et al. Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res 2008; 68: 1927–34

93. Kunimasa KT et al. Indole-3-carbinol suppresses tumor-induced angiogenesis by inhibiting tube formation and inducing apoptosis. Biosci Biotechnol Biochem 2008; 72: 2243–6

94. Rudzitis-Auth J et al. Indole-3-Carbinol Inhibits the Growth of Endometriotic Lesions by Suppression of Microvascular Network Formation. Nutrients 2022; 14(22): 4940

95. Fowke JH et al. Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000; 9: 773–9

96. Moore SC et al. Endogenous Estrogens, Estrogen Metabolites, and Breast Cancer Risk in Postmenopausal Chinese Women. J Natl Cancer Inst 2016; 108(10): djw103

97. Gao X et al. Endocrine disruption by indole-3-carbinol and tamoxifen: blockage of ovulation. Toxicol Appl Pharmacol 2002; 183: 179–88

98. Minich DM, Bland JS. A review of the clinical efficacy and safety of cruciferous vegetable phytochemicals. Nutr Rev 2007; 65: 259–67

99. Michnovicz JJ, Bradlow HL. Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer 1991; 16: 59–66

100. Moiseeva EP et al. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther 2007; 6: 3071–9

101. Cover CM et al. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 1999; 59: 1244–51

102. Cover CM et al. Indole-3-carbinol inhibits the expression of cyclin dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 1998; 273: 3838–47

103. Thomson CA et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Research and Treatment 2017; 165(1): 97–107

104. Papoutsis AJ et al. Gestational exposure to the AhR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin induces BRCA-1 promoter hypermethylation and reduces BRCA-1 expression in mammary tissue of rat offspring: Preventive effects of resveratrol. Mol Carcinog 2015; 54: 261–69

105. Guarnieri T. Aryl Hydrocarbon Receptor Connects Inflammation to Breast Cancer. Int J Mol Sci 2020; 21(15): 5264.nich

106. Kotsopoulos J et al. BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane. Br J Cancer 2014; 111(7): 1269–74

Medikamentöse Therapie in der Primärsituation des high-grade serösen Ovarialkarzinoms (S. 33–37)

F. Scheuerecker, B. Schmalfeldt

Literatur:

1.https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Eierstockkrebs/eierstockkrebs_nnod.html, aufgerufen 16.03.23 Zentrum für Krebsregisterdaten

2. Harter P et al. Therapiequalität des fortgeschrittenen Ovarialkarzinoms in Deutschland. Frauenarzt 2020; 61(3): 182–88

3. Torre LAet al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018; 68(4): 284–96

4. du Bois A et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009; 115(6): 1234–44

5. Piccart MJ et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92(9): 699–708

6. Burger RA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365(26): 2473–83

7. Perren TJ et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365(26): 2484–96

8. Wild R et al. Carboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to VRGF. Int J Cancer 2004; 110(3): 343–51

9. Pfisterer J et al. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. J Clin Oncol 2023; 41(4): 893–902

10. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science 2017, 355: 1152–58

11. Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol Oncol Res Pract 2017; 4: 4

12. Moore K et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2018; 379(26): 2495–505

13. Di Silvestro P et al. Overall survival at 7-year follow- up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib in the SOLO1/GOG 3004 trial. ESMO Congress 2022, Abstr. #517O

14. Gonzalez-Martin A et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian

Cancer. N Engl J Med 2019; 381(25): 2391–402

15. González-Martin A et al. PRIMA/ENGOT-OV26/ GOG-3012 study: Updated long-term PFS and safety. ESMO Congress 2022, Abstr. #530P

16. Ray-Coquard I et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med 2019; 381(25): 2416–28

17. Ray-Coquard I et al. Final overall survival results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer. ESMO Congress 2022, Abstr. #LBA29

18. Monk BJ et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22(9): 1275–89

19. Moore KN et al. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol 2021; 39(17): 1842–55

Das hepatozelluläre Karzinom (HCC): Leitliniengerechte interventionelle Therapieoptionen (S. 45–50)

T. J. Vogl, K. Eichler, W. Bechstein, S. Zeuzem, H. Adwan

Literatur:

1. Sung H et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71(3): 209–49
2. Villanueva A. Hepatocellular Carcinoma. N Engl J Med 2019; 380(15): 1450–62
3. Forner A et al. Hepatocellular carcinoma. Lancet 2018; 391: 1301–14
4. Choi JY et al. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014; 273(1): 30–50
5. Bruix J & Sherman M. Practice Guidelines Committee. Management of hepatocellular carcinoma. Hepatology 2005; 42(5): 1208–36
6. Huang JY et al. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma. Radiology 2020; 294(2): 329–39
7. Goode JA & Matson MB. Embolisation of cancer: what is the evidence? Cancer Imaging 2004; 4(2): 133–141
8. Vogl TJ & Gruber-Rouh T. HCC: Transarterial Therapies – What the Interventional Radiologist Can Offer. Dig Dis Sci 2019; 64(4): 959–67
9. Lencioni R et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 2016; 64(1): 106–16
10. Llovet JM et al. Hepatocellular Carcinoma. Nat Rev 2021; 7: 1–28
11. Mahnken AH. Transarterielle ablative Therapien des hepatozellulären Karzinoms. Radiologe 2014; 54: 685–93
12. Brown AM et al. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis. Meta-Analysis Cancer Med 2023; 12(3): 2590–9
13. Ai-Xue Sun et al. Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation. World Journal of Gastroenterology 2015; 21: 2997–3004
14. Adwan H et al. Percutaneous Thermal Ablation Therapy of Hepatocellular Carcinoma (HCC): Microwave Ablation (MWA) versus Laser-induced Thermotherapy (LITT). Diagnostics 2022; 12: 564
15. Du S. Comparisons of recurrence-free survival and overall survival between microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: A multiple centers retrospective cohort study with propensity score matching. PLoS One 2020; 15(1): e0227242
16. Suwa K et al. Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysis. Abdom Radiol (NY) 2021; 46(8): 3790–7
17. Kuroda H et al. Comparing the Safety and Efficacy of Microwave Ablation Using ThermosphereTM Technology versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021; 13(6): 1295

18. Vogl TJ et al. Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation. Abdom Imaging. 2015; 40(6): 1829–37

19. Abdelaziz A et al. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Surg Endosc 2014; 28(12): 3429–34

20. Lu MD et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol 2005; 40(11): 1054–60

21. Vogl TJ et al. Interventional oncological treatment of hepatocellular carcinoma (HCC) – A single-center long-term evaluation of thermoablation techiques like LITT, MWA, and TACE in a multimodal application over 26 years. Heliyon 2023, Mar 20; 9(4):e14646